Liver fibrosis is the end stage of most of liver diseases and is a serious health care problem worldwide.1 In the damaged liver, hepatic stellate cells (HSCs) are activated and produce excessive extracellular matrix components (ECM).2 Transforming growth factor (TGF)‐β is a key mediator of hepatic fibrosis and triggers the activation of HSCs, induces ECM synthesis and increases apoptosis of hepatocytes.3 Here, TGFB1 is linked to Hepatic fibrosis.